Using Fulvestrant for Intestinal Obstruction in Breast Cancer
Author Information
Author(s): Tang Jasmine YM, Rampaul Rajendra Singh, Cheung Kwok L
Primary Institution: University of Nottingham
Hypothesis
The role of fulvestrant in managing intestinal obstruction associated with lobular carcinoma has not been specifically described.
Conclusion
Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical benefit with less toxicity, in appropriately selected patients.
Supporting Evidence
- Fulvestrant is the only parenteral endocrine agent licensed for use in postmenopausal breast cancer.
- Both patients showed improvement in symptoms and tumor markers after treatment with fulvestrant.
- Fulvestrant may provide a means to initiate treatment in patients with intestinal obstruction.
Takeaway
Doctors used a medicine called fulvestrant to help two women with breast cancer who had trouble with their stomachs. It worked well and helped them feel better without needing stronger medicines.
Methodology
Case report detailing two patients treated with fulvestrant for intestinal obstruction due to metastatic lobular breast carcinoma.
Limitations
The study is based on only two case reports, limiting generalizability.
Participant Demographics
Two postmenopausal women with advanced lobular breast carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website